Immunotherapy advancements in high-grade serous ovarian cancer: From promise to practice - PubMed
3 hours ago
- #ovarian cancer
- #biomarkers
- #immunotherapy
- HGSC is a common, aggressive subtype of ovarian cancer with high recurrence and poor survival despite current treatments.
- Immunotherapy, which includes checkpoint inhibitors, vaccines, cell therapies, oncolytic viruses, and ADCs, is emerging as a potential treatment.
- ADCs targeting FRα and TROP2 show the most promising clinical results, with combinations using PARP inhibitors or anti-angiogenics offering synergy, but optimal sequencing is unclear.
- Biomarkers like HRD, PD-L1 expression, TMB, and neoantigen load may help select patients, but they are not yet fully validated.
- Toxicity management and multidisciplinary approaches are crucial for safely integrating immunotherapy, which holds promise for selected patients, with future focus on biomarker-driven trials and combination strategies.